165 related articles for article (PubMed ID: 26049405)
1. A new prognostic model for chemotherapy-induced febrile neutropenia.
Ahn S; Lee YS; Lee JL; Lim KS; Yoon SC
Int J Clin Oncol; 2016 Feb; 21(1):46-52. PubMed ID: 26049405
[TBL] [Abstract][Full Text] [Related]
2. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
3. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
4. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
[TBL] [Abstract][Full Text] [Related]
5. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
6. Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia.
Ko BS; Ahn S; Lee YS; Kim WY; Lim KS; Lee JL
Support Care Cancer; 2015 Sep; 23(9):2799-804. PubMed ID: 25663578
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
[TBL] [Abstract][Full Text] [Related]
8. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for refractory febrile neutropenia in urological chemotherapy.
Yasufuku T; Shigemura K; Tanaka K; Arakawa S; Miyake H; Fujisawa M
J Infect Chemother; 2013 Apr; 19(2):211-6. PubMed ID: 23011233
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
Ahn S; Lee YS; Chun YH; Kwon IH; Kim W; Lim KS; Kim TW; Lee KH
Support Care Cancer; 2011 Aug; 19(8):1151-8. PubMed ID: 20552376
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
[TBL] [Abstract][Full Text] [Related]
13. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?
Moon H; Choi YJ; Sim SH
PLoS One; 2018; 13(12):e0210019. PubMed ID: 30596803
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
Combariza JF; Lombana M; Pino LE; Arango M
Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
[TBL] [Abstract][Full Text] [Related]
17. Febrile Neutropenia in Patients with Solid Tumors Undergoing Intravenous Chemotherapy.
Moreira-Pinto J; Leão I; Palmela C; Branco F; Godinho J; Simões P; Leal-Costa L; Lopes F; Faria A; Casa-Nova M; Escária A; Costa F; Galvão I; Teixeira J; Passos-Coelho JL
Oncol Res Treat; 2020; 43(11):605-612. PubMed ID: 32818937
[TBL] [Abstract][Full Text] [Related]
18. Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study.
Agyeman P; Aebi C; Hirt A; Niggli FK; Nadal D; Simon A; Ozsahin H; Kontny U; Kühne T; Beck Popovic M; Leibundgut K; Bodmer N; Ammann RA
Pediatr Infect Dis J; 2011 Jul; 30(7):e114-9. PubMed ID: 21394050
[TBL] [Abstract][Full Text] [Related]
19. Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer.
Matsumoto T; Fujita M; Hirota T; Takeda S; Hirano R; Uchino J; Harada T; Watanabe K
J Infect Chemother; 2013 Apr; 19(2):202-7. PubMed ID: 23053498
[TBL] [Abstract][Full Text] [Related]
20. Risk index score for bacteremia in febrile neutropenic episodes in children with malignancies.
Spasova MI; Grudeva-Popova JG; Kostyanev SS; Genev ED; Stoyanova AA; Kirina VI; Moumdjiev IN
J BUON; 2009; 14(3):411-8. PubMed ID: 19810131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
